Slide 1: Investors Presentation Q4 FY23 exchange filing letter
May 11, 2023 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Investors Presentation Q4 FY23 – Orchid Pharma Limited (“the C
Slide 2: Annual Results FY23
Annual Results FY23
Slide 3: Safe Harbor
SAFE HARBOR FY2023 This presentation and the accompanying slides (the “Presentation”), which have been prepared by Orchid Pharma Ltd (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Total Income
FY2023 TOTAL INCOME 700 CAGR – 22% 600 566 685 500 505 457 400 300 200 100 0 FY20 FY21 FY22 FY23 11 May 2023 © Copyright OrchidPharma Ltd. All Rights Reserved 3
Slide 5: EBITDA
FY2023 EBITDA 120 15% 16% 14% 103 14% 100 12% 12% 80 10% 64 66 60 7% 8% 6% 40 34 4% 20 2% - 0% FY20 FY21 FY22 FY23 EBITDA in Cr. %age Income 11 May 2023 © Copyright OrchidPharma Ltd. All Rights Reserved 4
Slide 6: PAT
FY2023 PAT 40 5% 2% 20 0% 16 0 FY20 FY21 FY22 FY23 -5% -20 -53 -40 -9% -10% -88 -96 -60 -15% -80 -17% -20% -100 -21% -120 -25% PAT %age Income 11 May 2023 © Copyright OrchidPharma Ltd. All Rights Reserved 5
Slide 7: Expenses Breakup
FY2023 EXPENSES BREAKUP 300 60% 54% 55% 250 50% 200 45% 200 150 40% 36% 132 125 99 35% 100 33% 29% 30% 50 72 64 65 25% 60 0 20% FY20 FY21 FY22 FY23 Employee Expense Other Expenses %age to Income 11 May 2023 © Copyright OrchidPharma Ltd. All Rights Reserved 6
Slide 8: Leverage
FY2023 LEVERAGE 25% 24% 20% 21% 15% 10% 5% -7% 0% FY20 FY21 FY22 FY23 8% -5% -10% 12% -10% -15% % increase in total income % increase/Dec in expenses 11 May 2023 © Copyright OrchidPharma Ltd. All Rights Reserved 7
Slide 9: Long Term Debt from Bank
FY2023 LONG TERM DEBT FROM BANK 400 350 364 300 250 200 150 148 100 81 50 0 FY21 FY22 FY23 Long term Debt 11 May 2023 © Copyright OrchidPharma Ltd. All Rights Reserved 8
Slide 10: Summary Results
FY2023 SUMMARY RESULTS Rs. In cr Particulars Year 22-23 Year 21-22 Net Sales / Income from operations 666 557 Other Income 19 9 Total income 685 566 - - Raw material cost 385 314 Employee benefit expenses 65 60 Finance costs 32 32 Depreciation and amortization expense 55 87 Other expenses 132 125 To
Slide 11: Thank You!
OrchidPharma? ——— |S